Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng1, Yoon-Koo Kang2, Zhendong Chen3, Chao-Jung Tsao4, Shukui Qin5, Jun Suk Kim6, Rongcheng Luo7, Jifeng Feng8, Shenglong Ye9, Tsai-Sheng Yang10, Jianming Xu11, Yan Sun12, Houjie Liang13, Jiwei Liu14, Jiejun Wang15, Won Young Tak16, Hongming Pan17, Karin Burock18, Jessie Zou19, Dimitris Voliotis20
1National Taiwan University Hospital, Taipei, Taiwan
2ASAN Medical Centre, Songpa-gu, Seoul, Republic of Korea
3First Affiliated Hospital of Anhui Medical University, Hefei, China
4Chi Mei Medical Centre, Liou Ying Campus, Tainan, Taiwan
5Nanjing Bayi Hospital, Nanjing, China
6Korea University Guro Hospital, Seoul, Republic of Korea
7Nanfang Medical University Nanfang Hospital, Guangzhou, China
8Cancer Hospital of Jiangsu Province, Nanjing, China
9Zhongshan Hospital, Fudan University, Shanghai, China
10Chang Gung Memorial Hospital, Tao-Yuan, Taiwan
11Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China
12Cancer Institute and Hospital of CAMS, Beijing, China
13Southwest Hospital of Third Military Medical University, Chongqing, China
14First Affiliated Hospital of Dalian Medical University, Dalian, China
15Shanghai Changzheng Hospital, Shanghai, China
16Kyungpook National University Hospital, Daegu, Republic of Korea
17Sir Run Run Shaw Hospital, Zhejiang, China
18Bayer Schering Pharma, Wuppertal, Germany
19Bayer Schering Pharma, Shanghai, China
20Bayer HealthCare, Montville, NJ, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet Oncology
Tập 10
25-34
Thông tin tác giả